News | August 17, 2025
Anthem Biosciences posts Q1 FY26 PAT at Rs. 135.8 Cr
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
_256_384.jpg)
Marksans Pharma gets USFDA nod for acid reflux drug
Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines
Athena is also exploring the use of this technology for expanded carrier screening
The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage
Baruah will lead strategy, growth, and transformation across the HLS vertical, focusing on expanding digital health capabilities and accelerating AI adoption
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
Subscribe To Our Newsletter & Stay Updated
